Collecting data that show the most efficient and effective ways to clinically manage patients is becoming more important than ever in specialty pharmacy.
Gene-editing technology may be more effective reducing cardiovascular risks than targeting PCSK9.
A newer drug may preserve quality of life better than chemotherapy for patients with renal cell carcinoma.
Top news of the day from across the health care landscape.
The Approved Drug Products with Therapeutic Equivalence Evaluations is commonly known as the Orange Book.
The Guardian Connect System can alert patients of potential high or low glucose events up to an hour in advance.
Payers may achieve an additional discount for alirocumab (Praluent) if they agree to value-based contracts.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.